Severe asthma with fungal sensitization in a child: response to itraconazole therapy

Area of Science:

• Pulmonology
• Allergology
• Mycology

Background:

• Refractory asthma affects a significant patient population, often presenting complex diagnostic challenges.
• Fungal sensitization is increasingly recognized as a potential contributor to severe airway inflammation.
• Identifying specific patient subsets may lead to more targeted and effective therapeutic strategies.

Observation:

• A pediatric case of refractory asthma with persistent airway obstruction and extremely high immunoglobulin E levels (>20000 IU/mL) was observed.
• The patient exhibited severe eosinophilic airway infiltration but did not meet the diagnostic criteria for allergic bronchopulmonary aspergillosis.
• Despite not meeting formal criteria, the patient showed clear sensitization to multiple fungal species.

Findings:

• Adjunct therapy with the antifungal agent itraconazole led to a dramatic improvement in the patient's refractory asthma symptoms.
• This case highlights the potential benefit of antifungal treatment in severe asthma patients with fungal sensitization, even in the absence of classic allergic bronchopulmonary aspergillosis.
• Fungal sensitization may play a more significant role in severe asthma than currently recognized.

Implications:

• Clinicians should consider fungal sensitization in patients with severe, refractory asthma, even without a diagnosis of allergic bronchopulmonary aspergillosis.
• Antifungal therapy may represent a valuable adjunct treatment option for this underdiagnosed population.
• Further research into the mechanisms of fungal-induced asthma is warranted to optimize patient care.